Sort   by:  
 Page size 
MetabolomicsComparative metabolomic responses to gibberellic acid and 6-benzylaminopurine in Cunila menthoides Benth. (Lamiaceae): a contribution to understand the metabolic pathways
Little is known about the effects of 6-benzylaminopurine (BA) and gibberellic acid (GA3) on the synthesis of secondary metabolites in species of Lamiaceae. In this study, for the first time, the profile of secondary metabolites in plantlets of Cunila menthoides was characterized, using UPLC-ESI-Qq-o...
2018-05-24 | MTBLS581 | MetaboLights
TranscriptomicsTranscription profiling of Arabidopsis GA-treated wild type and etr1-1 plants to identify genes that are induced directly as a result of the GA treatment
This work is part of an existing collaboration between the two laboratories, funded by the EU (EU-RTN-INTEGA). Both parties will share the cost of this microarray experiment. Background: We have demonstrated that ethylene-insensitive mutants and wild type(col-0) Arabidopsis plants treated with an e...
ORGANISM(S): Arabidopsis thaliana 
2008-06-14 | E-GEOD-6150 | biostudies-arrayexpress
UnknownDolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Not available
S-EPMC9046096 | biostudies-literature
TranscriptomicsEffect of gibberellins on metabolism during rosette growth in Arabidopsis
To understand the effect of high and low GA levels on plant metabolism and development in Arabidopsis we made use of the GA biosynthesis inhibitor paclobutrazol (PBZ) and exogenously applied GA. The whole genome response at the translation level was assessed by immunopurification of polysomes from ...
ORGANISM(S): Arabidopsis thaliana 
2011-06-03 | E-GEOD-29699 | biostudies-arrayexpress
UnknownOnce-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.
Not available
S-EPMC12509724 | biostudies-literature
UnknownWeekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
Not available
S-EPMC5912750 | biostudies-literature
UnknownDolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Not available
S-EPMC9630157 | biostudies-literature
UnknownDolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Not available
S-EPMC7614690 | biostudies-literature
UnknownChildren living with HIV in Europe: do migrants have worse treatment outcomes?
Not available
S-EPMC9293243 | biostudies-literature
UnknownODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Not available
S-EPMC7809782 | biostudies-literature
Sort   by:  
 Page size